Evonik and AkzoNobel Start Building Electrolysis Plant

Germany’s Evonik and AzkoNobel of the Netherlands have broken ground to start construction of a new membrane electrolysis plant in Ibbenbüren. The two companies set up a 50:50 joint venture last June for the production of chlorine and potassium hydroxide solution at AkzoNobel’s site in Germany.

The facility is scheduled to go on stream by the fourth quarter of 2017. Annual nameplate capacity will be about 130,000 t of potassium hydroxide solution and around 82,000 t of chlorine.

Werner Fuhrmann, member of AkzoNobel’s executive committee responsible for specialty chemicals, said the plant would set a new production benchmark. He explained: “It will improve the ecological footprint of every ton of chlorine we produce in Ibbenbüren by 25 to 30 percent. This will result in less energy use and fewer CO2 emissions, while there will also be clear benefits for the local chemical cluster.”

Under EU legislation, mercury-based chlorine and caustic production has to be discontinued by the end of 2017.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.